Loading...
In December 2025, the U.S. FDA approved tradipitant (Nereus) for prevention of motion-induced vomiting in adults.
Vomiting can be caused by stimulation of neurokinin-1 (NK1) receptors in the central nervous system. Because vomiting in people with motion sickness is mediated through this pathway, researchers developed tradipitant, an NK1 receptor antagonist, to prevent this symptom. Several other agents in this drug class have been approved for preventing chemotherapy-induced and postoperative nausea and vomiting.
Two industry-sponsored studies contributed to FDA approval.
A published study involved 365 adults with a history of vomiting from motion sickness, typically during boat travel. Participants were randomly assigned…